Journal of
Clinical and Pharmaceutical Research
REVIEW OPEN ACCESS

Analysing Impurities and Degradation Products

Slesha Kumar Kosuru*,Tadi Suvarna, M. Asha Jyothi, D. Jayasri, P.V.S.S. Saranya, M.M.V.V. Sai Durga

Department of Pharmaceutical Analysis & Quality Assurance, Lydia College of Pharmacy, Ravulapalem, Andhra Pradesh, India.

ARTICLE INFO

Article History:
Received: 24.05.2023
Revised: 20.06.2023
Accepted: 15.07.2023

Keywords :
Degradation Products
Impurities
Pharmaceutical Analysis

Corresponding Author:
Mr. Slesha Kumar Kosuru M.Pharm.,
Assistant Professor,
Department of Pharmaceutical Analysis & Quality Assurance,
Lydia College of Pharmacy,
Ravulapalem, Andhra Pradesh, India.
Email: sleshakumar555@gmail.com

ABSTRACT

In the realm of pharmaceutical analysis, the analysis of impurities and degradation products takes centre stage, and its significance cannot be overstated. These undesired substances can profoundly impact the quality, safety and efficacy of pharmaceutical products, necessitating rigorous analytical methods and processes at every stage of drug development and manufacturing. Forced degradation studies are instrumental in identifying and characterizing impurities that may arise within a product, a pivotal source of information for quality control and regulatory compliance. Stability testing is integral to the batch release process, ensuring each product batch meets established stability criteria before entering the market. Stability testing and degradation studies are indispensable constituents of pharmaceutical analysis. They substantially contribute to preserving the quality, safety, and efficacy of pharmaceutical products. Beyond their regulatory mandates, these studies serve as proactive instruments for comprehending and supervising product stability across their life cycles. The insights gleaned from these endeavours inform critical judgments during drug development and manufacturing, ultimately assuring the welfare of patients and compliance with stringent regulatory requisites.

Introduction

In the realm of pharmaceutical analysis, the analysis of impurities and degradation products takes center stage, and its significance cannot be overstated. These undesired substances can profoundly impact the quality, safety and efficacy of pharmaceutical products, necessitating rigorous analytical methods and processes at every stage of drug development and manufacturing [1].

One finds that these substances are multifaceted in nature, encompassing a broad range of compounds, including organic and inorganic impurities, residual solvents and degradation products. Impurities often result from various stages of synthesis or manufacturing, while degradation products emerge due to environmental factors like light, heat, humidity or chemical interactions.

Precise and reliable analytical techniques, such as high-performance liquid chromatography (HPLC), gas chromatography (GC) and mass spectrometry (MS) are indispensable tools for the detection and quantification of these impurities and degradation products. These methods offer in-depth insights into the chemical composition and concentration of these substances, forming the cornerstone of effective analysis.

To meet these challenges head-on, skilled analysts and researchers invest considerable effort into method development. These methodologies are meticulously crafted to efficiently separate impurities and degradation products from the active pharmaceutical ingredient, enabling their accurate detection and quantification [2].

Furthermore, regulatory requirements from agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) place stringent demands on pharmaceutical manufacturers to adhere to specific guidelines pertaining to impurities and degradation products. These regulations are in place to ensure the safety and efficacy of pharmaceutical products.

The pharmaceutical industry also conducts forced degradation studies, which subject drug products to a range of stress conditions, effectively mimicking the product's potential experiences during its shelf life. The aim is to generate degradation products and analyse them comprehensively, discerning their impact on product quality.

Assessing the safety and efficacy of pharmaceutical products is an integral part of the process. Certain impurities may exhibit toxic properties or trigger adverse reactions in patients. Therefore, their control and continuous monitoring are essential.

Quality control laboratories within pharmaceutical manufacturing facilities play a pivotal role in the ongoing scrutiny and testing of products for impurities and degradation products. Their responsibilities encompass the routine evaluation of each product batch to ensure alignment with quality standards and regulatory compliance.

Method validation is an essential component of this process, requiring rigorous testing to demonstrate the precision, accuracy, specificity and robustness of the analytical methods used. Successful validation is a crucial step in achieving regulatory approval.

Stability testing is yet another aspect of the analysis journey. Pharmaceutical products are subjected to variations in temperature and humidity to observe their behaviour over time. These studies offer insights into how impurities and degradation products may form or change during the product's shelf life.

In the face of these analytical challenges, the pharmaceutical industry conducts risk assessments to gauge the potential implications of impurities and degradation products. Based on the risk level, mitigation strategies may be introduced to minimize or eliminate these undesired substances throughout drug development and manufacturing.

The analysis of impurities and degradation products in pharmaceuticals is an indispensable endeavour, ensuring that products meet the highest standards of quality, safety and efficacy. Rigorous and dependable analytical methods, utilized throughout the drug development and manufacturing process, serve as the linchpin of this crucial aspect of pharmaceutical analysis [3].

Detecting and characterizing impurities

In the sphere of pharmaceutical analysis, the discernment and characterization of impurities emerge as a paramount endeavour. These impurities, irrespective of their organic, inorganic or degradation origins, exert a substantial influence on the quality, safety and efficacy of pharmaceutical products. Consequently, the identification and characterization of these impurities represent pivotal steps in ensuring that the final pharmaceutical product adheres to the stringent standards set forth by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

TECHNIQUES FOR IMPURITY DETECTION

High-Performance Liquid Chromatography (HPLC)

High-Performance Liquid Chromatography, renowned for its efficacy, stands as one of the most widely embraced techniques for impurity detection. Its aptitude for segregating components within a mixture permits the isolation and identification of impurities. Modern HPLC systems are endowed with exceptional sensitivity and resolution, rendering them invaluable tools in the analysis of pharmaceutical samples.

Gas Chromatography (GC)

Gas Chromatography proficiency in the detection of volatile and gaseous impurities is well-recognized. It accomplishes separation predicated on the vaporization properties of compounds and is frequently utilized for the evaluation of residual solvents.

Mass Spectrometry (MS)

Mass Spectrometry, a robust instrument, is indispensable for both the detection and characterization of impurities. It furnishes comprehensive insights into the molecular weight, structure and composition of compounds, thereby facilitating the identification of unknown impurities.

Nuclear Magnetic Resonance (NMR) Spectroscopy

Nuclear Magnetic Resonance spectroscopy role is indispensable in characterizing the structures of impurities. It furnishes revelations concerning the three-dimensional arrangement of atoms in a molecule, thereby contributing to the determination of impurity identity.

Ultraviolet-Visible (UV-Vis) Spectroscopy

UV-Visible spectroscopy assists in impurity detection predicated on the absorbance characteristics of impurities in the UV or visible light spectrum. It is also valuable for evaluating the purity of the active pharmaceutical ingredient.

Infrared (IR) Spectroscopy

IR spectroscopy imparts insights into the functional groups present in a compound, which in turn facilitates the identification of impurities [4].

CHARACTERIZATION OF IMPURITIES

Structural Elucidation

After the detection of an impurity, the next crucial stride involves the determination of its structure. Typically, this entails a fusion of techniques such as NMR, MS and IR spectroscopy. By unravelling the structure of the impurity, its potential impact on the drug product can be assessed.

Quantification

The precise quantification of impurities is essential to evaluate their safety and compliance with regulatory thresholds. HPLC, GC, and MS, among other methods, serve as the bedrock for precise quantification.

Regulatory Compliance

The FDA, EMA and their counterparts worldwide have established stringent directives and thresholds for impurities within pharmaceutical products. Manufacturers are compelled to ensure that their products conform to these standards to secure regulatory approval.

Method Validation

Analytical methods employed for impurity detection and quantification must undergo rigorous validation procedures. These procedures confirm the methods' accuracy, precision, specificity and robustness.

Risk Assessment

Pharmaceutical manufacturers frequently undertake risk assessments to gauge the potential implications of impurities. The level of risk delineates the actions taken to regulate or eliminate impurities [5].

STABILITY STUDIES

Forced Degradation Studies

To comprehend how impurities may evolve or emerge over time, pharmaceutical products are subjected to rigorous stress conditions, simulating their potential experiences during storage. Forced degradation studies are pivotal in evaluating the effects of impurities on product stability.

The identification and characterization of impurities in pharmaceutical products assume a pivotal role in assuring their safety, efficacy, and quality. This meticulous process relies upon a spectrum of sophisticated analytical techniques and instruments, unwavering compliance with regulatory benchmarks, and a resolute commitment to exhaustive method validation. It stands as an elemental facet of pharmaceutical analysis, one that upholds public health and guarantees that patients receive pharmaceutical products of the utmost quality. Quality assurance serves as a hallmark of quality control, facilitating the collection of empirical data related to variations in a product's attributes, including its identity, potency, quality, and purity as it evolves over time.

ENVIRONMENTAL FACTORS IN STABILITY TESTING

Temperature

Stability investigations include various temperature conditions, from long-term storage under controlled room temperature to accelerated stability testing at elevated temperatures, simulating extended-term product performance.

Humidity

Moisture content significantly affects the physical and chemical stability of pharmaceuticals. Products sensitive to moisture require meticulous humidity level monitoring.

Light

Photochemical degradation due to light exposure, especially UV and visible light, impacts certain pharmaceuticals. Light exposure testing is vital for assessing the stability of light-sensitive products.

Oxygen

Oxidation reactions, a common source of instability, necessitate the control of oxygen content in both product packaging and storage environments.

pH Levels

Variations in pH can influence product stability, a concern of particular relevance for formulations sensitive to pH changes.

Biological Threats

Some pharmaceuticals are vulnerable to biological contaminants, particularly microorganisms. Hence, microbiological stability testing is essential for products prone to microbial contamination.

TYPES OF STABILITY TESTING

Long-Term Stability Testing

This category involves the extended storage of pharmaceutical product samples under meticulously controlled conditions, mimicking real-world shelf-life preservation.

Accelerated Stability Testing

Accelerated protocols test products under intensified stress conditions, such as elevated temperatures and humidity, offering expedited predictions of long-term stability.

Intermediate Stability Testing

Focused on intermediate conditions, this testing reveals how products fare during transportation and transient storage.

Photo-Stability Testing

Simulating controlled light conditions; this testing unveils a product's susceptibility to photochemical degradation [6].

Conclusion

Forced degradation studies are instrumental in identifying and characterizing impurities that may arise within a product, a pivotal source of information for quality control and regulatory compliance. Stability testing is integral to the batch release process, ensuring each product batch meets established stability criteria before entering the market. Stability testing and degradation studies are indispensable constituents of pharmaceutical analysis. They substantially contribute to preserving the quality, safety, and efficacy of pharmaceutical products. Beyond their regulatory mandates, these studies serve as proactive instruments for comprehending and supervising product stability across their life cycles. The insights gleaned from these endeavours inform critical judgments during drug development and manufacturing, ultimately assuring the welfare of patients and compliance with stringent regulatory requisites.

References

1. Rubén M. Maggio, Natalia L. Calvo, Silvana E. Vignaduzzo, Teodoro S. Kaufman. Pharmaceutical impurities and degradation products: Uses and applications of NMR techniques. Journal of Pharmaceutical and Biomedical Analysis. 2014; 101: 102-22.
2. Prajapati Prajesh and Agrawal YK. Analysis and impurity identification in pharmaceuticals. Reviews in Analytical Chemistry. 2014; 33(2): 123-33.
3. USP Chapters <1086> Impurities in drug substances and drug products. USP 41. The United States Pharmacopeial Convention. August 1, 2018.
4. ICH Harmonised Tripartite Guideline. Impurities in new drug substances. Q3A(R2). ICH. 25 October 2006.
5. Kelce WR, Castle KE, Ndikum-Moffor FM, Patton LM. Drug substance and drug product impurities, now what? MOJ Toxicology. 2017; 3(1):9-13.
6. Baertschi SW. Analytical methodologies for discovering and profiling degradation related impurities. Trends in Analytical Chemistry. 2006; 25(8): 758-67.